elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Durvalumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Durvalumab
RIS
0.004
(Research Intensity Score)
Papers
210
Top papers
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · 972 citations
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
2024 · 350 citations
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
2022 · 1141 citations
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
2024 · 357 citations
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
2024 · 274 citations
Small Cell Lung Cancer
2025 · 158 citations
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · 2293 citations
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
2024 · 142 citations
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
2025 · 69 citations
Newest papers
Results from the safety lead-in for a phase 1b/2 study of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.
2026 · 2 citations
Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance
2026 · 1 citations
Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment
2026 · 1 citations
Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment
2026 · 1 citations
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
2026 · 1 citations
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer
2026 · 1 citations
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
2026
Immunotherapy in urological cancers: new paradigms and a systematic review of clinical trials and real-world evidence
2026
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis
2026
Browse all papers →
Durvalumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Durvalumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link